Valuation: Verastem, Inc.

Market Cap 50Cr 43Cr 41Cr 37Cr 70Cr 4.77TCr 71Cr 478.37Cr 187.36Cr 2.38TCr 187.81Cr 183.65Cr 7.84TCr P/E 2026 *
-3.59x
P/E 2027 * -5.07x
Enterprise Value 34Cr 29Cr 27Cr 25Cr 47Cr 3.19TCr 48Cr 320.51Cr 125.53Cr 1.59TCr 125.83Cr 123.05Cr 5.25TCr EV / Sales 2026 *
3.29x
EV / Sales 2027 * 1.63x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day-1.90%
1 week-6.41%
Current month-1.90%
1 month+26.44%
3 months-2.57%
6 months-9.68%
Current year-26.30%
1 week 5.54
Extreme 5.54
6.31
1 month 4.3
Extreme 4.3
6.46
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
21/05/26 Free

Director

36,000 0.0410%
21/05/26 Free

Director

36,000 0.0410%
21/05/26 Free

Chairman

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-1.90%-6.41%-6.41%-47.27% 50Cr
+0.05%+3.08%+38.17%+66.77% 5.67TCr
+0.17%-6.30%+23.11%+61.62% 5.2TCr
+1.84%+1.27%-14.06%-13.50% 2.33TCr
-0.15%-6.00%-9.42%+344.47% 2.13TCr
+1.00%-2.36%+31.75%-26.39% 1.74TCr
+9.91%-2.51%+188.84%+326.19% 1.48TCr
+3.83%-1.34%+47.77%+165.22% 1.38TCr
+1.61%+0.56%+439.92%+166.12% 1.21TCr
+3.14%-12.56%+59.51%+149.39% 1.11TCr
Average +1.95%-2.74%+79.92%+119.26% 2.23TCr
Weighted average by Cap. +1.44%-1.96%+57.50%+109.00%

Financials

2026 *2027 *
Net sales 10Cr 8.85Cr 8.27Cr 7.59Cr 14Cr 971Cr 15Cr 97Cr 38Cr 484.22Cr 38Cr 37Cr 1.6TCr 18Cr 16Cr 14Cr 13Cr 25Cr 1.7TCr 25Cr 170.63Cr 67Cr 847.73Cr 67Cr 66Cr 2.8TCr
Net income -17Cr -14Cr -13Cr -12Cr -23Cr -1.58TCr -24Cr -158.37Cr -62Cr -786.78Cr -62Cr -61Cr -2.6TCr -14Cr -12Cr -12Cr -11Cr -20Cr -1.35TCr -20Cr -135.92Cr -53Cr -675.27Cr -53Cr -52Cr -2.23TCr
Net Debt -16Cr -14Cr -13Cr -12Cr -23Cr -1.57TCr -24Cr -157.86Cr -62Cr -784.29Cr -62Cr -61Cr -2.59TCr -21Cr -18Cr -17Cr -16Cr -29Cr -2TCr -30Cr -200.53Cr -79Cr -996.28Cr -79Cr -77Cr -3.29TCr
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
03/26/03 $5.690 -1.90% 12,88,075
31/26/31 $5.800 -4.92% 18,57,262
30/26/30 $6.100 +1.50% 14,51,955
29/26/29 $6.010 -3.53% 22,49,888
28/26/28 $6.230 +2.47% 12,75,019
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.690USD
Average target price
15.00USD
Spread / Average Target
+163.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock